Investigating personalized treatment options for Idiopathic Pulmonary Fibrosis using genetic information.
Official title: 1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
Funded at Univ of Massachusetts Med Sch Worcester · NIH-11075126 · Data updated 2026-11-12
This study is looking to help people with Idiopathic Pulmonary Fibrosis (IPF) by using their genetic information to find the best treatments for them, so they can get care that’s more personalized and effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Massachusetts Med Sch Worcester NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project start | August 31, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $977,233 |
| NIH project number | 5UH3HL145266-07 |
| Project ID | NIH-11075126 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Idiopathic Pulmonary Fibrosis who are willing to provide genetic samples and participate in a precision medicine trial.
✕Less likely to help
Patients with other forms of interstitial lung diseases or those not diagnosed with Idiopathic Pulmonary Fibrosis may not benefit from this research.
What this research studies
This research focuses on improving the diagnosis and treatment of Idiopathic Pulmonary Fibrosis (IPF) by utilizing genetic information to tailor antifibrotic therapies. By partnering with the Pulmonary Fibrosis Foundation, the study aims to collect and analyze biological samples and patient data to identify genetic variants that influence treatment response. The goal is to move away from a 'one size fits all' approach and develop precision medicine strategies that can better manage this challenging condition. Patients will be involved in a trial that assesses how their genetic makeup can guide more effective treatment options.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment strategies for patients with Idiopathic Pulmonary Fibrosis.
How similar studies have gone: Previous research has shown promise in using genetic information to tailor treatments for various conditions, indicating that this approach could be beneficial for IPF as well.
Where this research is happening
-
Univ of Massachusetts Med Sch Worcester
Worcester, United States Active
Researchers
- Principal investigator: Martinez, Fernando J — Univ of Massachusetts Med Sch Worcester
- Study coordinator: Martinez, Fernando J
Related research
Other NIH-funded projects on the same topics.
-
Investigating personalized treatment options for Idiopathic Pulmonary Fibrosis using genetic information
This study is looking to make treatments for Idiopathic Pulmonary Fibrosis (IPF) better by using genetic information to find out how different people respond to medications like N-Acetylcysteine, so that doctors can provide more personalized care for patients with lung diseases.
-
Investigating the role of the complement pathway in lung diseases
This study is looking at how certain proteins in your body might help us understand the progression of idiopathic pulmonary fibrosis and similar lung diseases, so we can find better treatments tailored just for you.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
How lung cells and their surroundings drive fibrosis in interstitial lung diseases
A study to understand how airway cells, surrounding tissue, and their environment contribute to progressive scarring in interstitial lung diseases.
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.